Scientists track rare eye disease to pave way for future treatments
NCT ID NCT04591483
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 25 people aged 10 and older with Stargardt-like macular dystrophy (STDG3), a rare inherited eye disease that causes vision loss. Over three years, researchers will measure changes in the retina using eye exams, imaging, and vision tests. The goal is to understand how the disease progresses naturally, which is essential for designing future clinical trials for potential treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study will provide crucial data on how STDG3 progresses, which could help design future treatment trials.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any therapy, and results may not lead directly to a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STARGARDT-LIKE MACULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.